Sickle Cell
A Areas medical research research area page covering state of the field, key trials running, recent readouts and what is close to approval, alongside the 7
Beam's risto-cel hits endpoint in sickle cell BEACON trial
Beam Therapeutics' base editing therapy risto-cel achieved its primary endpoint of 12 months without severe pain crises in a key trial, setting up a...
FDA Approves First New Head and Neck Cancer Therapy in a Decade
The FDA has granted accelerated approval to Janssen's Rybrevant Faspro for recurrent or metastatic head and neck squamous cell carcinoma, based on a...
Artiva Biotherapeutics halts AlloNK trial and cuts 94% of staff after patient deaths
Artiva Biotherapeutics is ending development of its AlloNK cell therapy and laying off most employees after two patient deaths in a Phase 2a trial...
EVOKE-03 Trial: Sacituzumab Fails to Boost Survival
The phase III EVOKE-03 trial found adding sacituzumab govitecan to pembrolizumab did not significantly improve survival in untreated metastatic...
GSK's risvutatug rezetecan shows 18.5-month median overall survival
GSK and Hansoh Pharma's antibody-drug conjugate risvutatug rezetecan achieved a median overall survival of 18.5 months in a phase 3 trial for...
Novartis, BMS Pause CAR-T Autoimmune Trials
Novartis and Bristol Myers Squibb have paused clinical trials of their CAR T-cell therapies for autoimmune diseases following severe adverse events.
T Cell Therapy Treats Atopic Dermatitis
A Lancet comment published August 21, 2026, discusses rezpegaldesleukin, a novel therapy designed to expand regulatory T cells.